For UK pharmaceutical and life sciences leaders
Your reps are covering the miles but losing the room
HCPs have less time, more options, and higher expectations than a decade ago. Without the right tools, training, and channel mix, field visits consume budget without shifting prescribing behaviour.
Two minutes. Solva follows up with specific field effectiveness options.
- Sales reps struggling to secure meetings with key HCPs
- Low engagement rates during in-person or virtual calls
- HCPs expressing dissatisfaction with the relevance of information provided
- Stagnant or declining market share for new pharmaceutical products
- Inefficient allocation of field force resources and time
- Suboptimal targeting of healthcare professionals (HCPs)
- Reduced return on investment (ROI) for pharmaceutical companies due to ineffective sales efforts
- Increased operational costs from inefficient field force deployment and travel
- Delayed patient access to innovative treatments
- Suboptimal prescribing decisions due to lack of current drug information
- Damage to pharmaceutical company reputation among HCPs
- Perception of irrelevance or outdated engagement methods
47% of HCPs value interactions with pharmaceutical companies (PM Society, 2023)
Source: https://pmsociety.org.uk/news/what-does-the-pharmaceutical-representative-of-the-future-look-like/
Frequently asked questions
Why does this problem persist?
The traditional sales model is no longer effective as healthcare professionals (HCPs) have less time and prefer diverse engagement channels. Field teams often lack the tools and training to deliver personalized, data-driven interactions that truly resonate with HCPs.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.